KDR and breast cancer: For example, paclitaxel encapsulated aldehyde polyethylene glycol-polylactide (PEG-PLGA) conjugated to a VEGFR2-inhibiting peptide showed increased internalization in HUVECs in vitro as well as potent activity against breast cancer models in vivo (Yu et al., 2010).